Structure-based chemogenomics: analysis of protein family landscapes.

Analysis of the three-dimensional structures of protein ligand complexes provides valuable insight into both the common interaction patterns within a target family and the discriminating features between the different members of a target family. Knowledge of the common interaction patterns helps to design target family focused chemical libraries for hit finding, while the discriminating features can be exploited to optimize the selectivity profile of a lead compound against particular member of a target family. Herein, we review the computational tools which have been developed to analyze crystal structures of members of a target family.

[1]  Renxiao Wang,et al.  The PDBbind database: methodologies and updates. , 2005, Journal of medicinal chemistry.

[2]  M Pastor,et al.  A novel strategy for improving ligand selectivity in receptor-based drug design. , 1995, Journal of medicinal chemistry.

[3]  Gerhard Klebe,et al.  What Can We Learn from Molecular Recognition in Protein–Ligand Complexes for the Design of New Drugs? , 1996 .

[4]  G. Klebe,et al.  A new method to detect related function among proteins independent of sequence and fold homology. , 2002, Journal of molecular biology.

[5]  Bingcheng Wang,et al.  Chemometrical Classification of Ephrin Ligands and Eph Kinases Using GRID/CPCA Approach , 2003, J. Chem. Inf. Comput. Sci..

[6]  Gerhard Klebe,et al.  Utilising structural knowledge in drug design strategies: applications using Relibase. , 2003, Journal of molecular biology.

[7]  Christoph Steinbeck,et al.  Classification and comparison of ligand-binding sites derived from grid-mapped knowledge-based potentials. , 2006, Journal of molecular graphics & modelling.

[8]  Oriana Tabarrini,et al.  Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: Toward more specific ligands , 2000, J. Comput. Aided Mol. Des..

[9]  Robert P. Sheridan,et al.  FLOG: A system to select ‘quasi-flexible’ ligands complementary to a receptor of known three-dimensional structure , 1994, J. Comput. Aided Mol. Des..

[10]  H. Matter,et al.  Insights into the bile acid transportation system: The human ileal lipid‐binding protein‐cholyltaurine complex and its comparison with homologous structures , 2002, Proteins.

[11]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[12]  G. Klebe,et al.  Knowledge-based scoring function to predict protein-ligand interactions. , 2000, Journal of molecular biology.

[13]  Hans Matter,et al.  Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. , 2006, Journal of medicinal chemistry.

[14]  Nicola D. Gold,et al.  A Searchable Database for Comparing Protein-Ligand Binding Sites for the Analysis of Structure-Function Relationships , 2006, J. Chem. Inf. Model..

[15]  T. Poulos,et al.  Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors. , 2003, Journal of medicinal chemistry.

[16]  P J Goodford,et al.  A search for specificity in DNA-drug interactions. , 1994, Journal of Molecular Graphics.

[17]  Bernard Pirard,et al.  Peroxisome Proliferator-Activated Receptors target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis , 2003, J. Comput. Aided Mol. Des..

[18]  Peter Goodford,et al.  The Basic Principles of GRID , 2006 .

[19]  Angelo Carotti,et al.  Screening of Matrix Metalloproteinases Available from the Protein Data Bank: Insights into Biological Functions, Domain Organization, and Zinc Binding Groups , 2007, J. Chem. Inf. Model..

[20]  John P. Overington,et al.  PDBLIG: classification of small molecular protein binding in the Protein Data Bank. , 2004, Journal of medicinal chemistry.

[21]  R. Venkataraghavan,et al.  Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..

[22]  Mika A. Kastenholz,et al.  GRID/CPCA: a new computational tool to design selective ligands. , 2000, Journal of medicinal chemistry.

[23]  E. Jacoby,et al.  Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.

[24]  Jeffrey Jie-Lou Liao,et al.  Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors , 2007 .

[25]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[26]  G. Klebe,et al.  From the Similarity Analysis of Protein Cavities to the Functional Classification of Protein Families Using Cavbase , 2006, Journal of Molecular Biology.

[27]  D. Rognan.  Chemogenomic approaches to rational drug design , 2007, British journal of pharmacology.

[28]  Gerhard Klebe,et al.  KNOBLE: a knowledge-based approach for the design and synthesis of readily accessible small-molecule chemical probes to test protein binding. , 2007, Angewandte Chemie.

[29]  Gerard J Kleywegt,et al.  Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. , 2003, Angewandte Chemie.

[30]  J. Macgregor,et al.  Analysis of multiblock and hierarchical PCA and PLS models , 1998 .

[31]  M. Murcko,et al.  Chemogenomic approaches to drug discovery. , 2001, Current opinion in chemical biology.

[32]  T. Fox.  Protein Selectivity Studies Using GRID‐MIFs , 2006 .

[33]  D. C. Sullivan,et al.  AutoShim: Empirically Corrected Scoring Functions for Quantitative Docking with a Crystal Structure and IC50 Training Data. , 2008 .

[34]  Eric J. Martin,et al.  AutoShim: Empirically Corrected Scoring Functions for Quantitative Docking with a Crystal Structure and IC50 Training Data , 2008, J. Chem. Inf. Model..

[35]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[36]  Bruce L. Bush,et al.  Extending the trend vector: The trend matrix and sample-based partial least squares , 1994, J. Comput. Aided Mol. Des..

[37]  H. Matter,et al.  Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. , 2002, Journal of medicinal chemistry.

[38]  S. Pickett,et al.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.

[39]  K. Bleicher,et al.  Chemogenomics: bridging a drug discovery gap. , 2002, Current medicinal chemistry.

[40]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[41]  Alex M Aronov,et al.  Toward a pharmacophore for kinase frequent hitters. , 2004, Journal of medicinal chemistry.

[42]  T. Andersson,et al.  Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. , 2001, Journal of medicinal chemistry.

[43]  T. Klabunde.  Chemogenomic approaches to drug discovery: similar receptors bind similar ligands , 2007, British journal of pharmacology.

[44]  Paul Geladi,et al.  Principal Component Analysis , 1987, Comprehensive Chemometrics.

[45]  A. Bergner,et al.  Structural Aspects of Binding Site Similarity: A 3D Upgrade for Chemogenomics , 2005 .

[46]  Paul N. Mortenson,et al.  Diverse, high-quality test set for the validation of protein-ligand docking performance. , 2007, Journal of medicinal chemistry.

[47]  Robert P Sheridan,et al.  A simple method for visualizing the differences between related receptor sites. , 2002, Journal of molecular graphics & modelling.

[48]  P. Caron,et al.  Classifying protein kinase structures guides use of ligand‐selectivity profiles to predict inactive conformations: Structure of lck/imatinib complex , 2007, Proteins.

[49]  Gabriele Cruciani,et al.  Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. , 2002, Journal of medicinal chemistry.

[50]  G. Klebe,et al.  Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. , 2004, Journal of medicinal chemistry.

[51]  Eric J. Martin,et al.  Surrogate AutoShim: Predocking into a Universal Ensemble Kinase Receptor for Three Dimensional Activity Prediction, Very Quickly, without a Crystal Structure , 2008, J. Chem. Inf. Model..

[52]  Thierry Langer,et al.  Molecule-pharmacophore superpositioning and pattern matching in computational drug design. , 2008, Drug discovery today.

[53]  A. Vulpetti,et al.  Sturcture-Based Approaches to Improve Selectivity: CDK2—GSK3β Binding Site Analysis. , 2005 .

[54]  Eyke Hüllermeier,et al.  Functional Classification of Protein Kinase Binding Sites Using Cavbase , 2007, ChemMedChem.

[55]  Didier Rognan,et al.  sc-PDB: an Annotated Database of Druggable Binding Sites from the Protein Data Bank , 2006, J. Chem. Inf. Model..

[56]  Gerhard Klebe,et al.  From Structure to Function: A New Approach to Detect Functional Similarity among Proteins Independent from Sequence and Fold Homology. , 2001, Angewandte Chemie.

[57]  Taebo Sim,et al.  A general strategy for creating "inactive-conformation" abl inhibitors. , 2006, Chemistry & biology.

[58]  Gerhard Klebe,et al.  Predicting binding modes, binding affinities and ‘hot spots’ for protein-ligand complexes using a knowledge-based scoring function , 2000 .

[59]  H Matter,et al.  Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins. , 1999, Journal of medicinal chemistry.

[60]  G. Klebe,et al.  Identification and mapping of small-molecule binding sites in proteins: computational tools for structure-based drug design. , 2002, Farmaco.

[61]  Gabriele Cruciani,et al.  A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application , 2007, J. Chem. Inf. Model..

[62]  Renxiao Wang,et al.  The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. , 2004, Journal of medicinal chemistry.

[63]  Gerhard Klebe,et al.  Relibase: design and development of a database for comprehensive analysis of protein-ligand interactions. , 2003, Journal of molecular biology.

[64]  Malcolm J. McGregor,et al.  A Pharmacophore Map of Small Molecule Protein Kinase Inhibitors , 2007, J. Chem. Inf. Model..

[65]  Gerhard Klebe,et al.  Identification and Mapping of Small-Molecule Binding Sites in Proteins: Computational Tools for Structure-Based Drug Design. , 2002 .

[66]  Rajiv Sharma,et al.  Design and synthesis of protein superfamily-targeted chemical libraries for lead identification and optimization. , 2005, Current medicinal chemistry.

[67]  Roman Fedorov,et al.  Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases. , 2005, Journal of medicinal chemistry.